<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Spondyloarthritis in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Spondyloarthritis in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Spondyloarthritis in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marisa Klein-Gitelman, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Suzanne C Li, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children, the spondyloarthropathies are a group of rheumatic diseases characterized by enthesitis and arthritis, most frequently involving the lower extremities initially and, in a variable proportion of cases, the sacroiliac and spinal joints later in the disease course [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The clinical aspects of childhood spondyloarthritis, particularly enthesitis related arthritis (ERA) and juvenile ankylosing spondylitis (JAS), are discussed here. Other categories of juvenile idiopathic arthritis (JIA) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6412.html" rel="external">
          "Classification of juvenile idiopathic arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6413.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13512.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Course, prognosis, and complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6400.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6414.html" rel="external">
          "Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6428.html" rel="external">
          "Polyarticular juvenile idiopathic arthritis: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16366.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Management and prognosis"
         </a>
         .)
        </p>
        <p>
         Detailed discussions of the corresponding disorders in the adult, including psoriatic arthritis, reactive arthritis, and ankylosing spondylitis (AS), are presented separately. Arthritis associated with inflammatory bowel disease (IBD) and other gastrointestinal diseases is also discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/95962.html" rel="external">
          "Overview of the clinical manifestations and classification of spondyloarthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7795.html" rel="external">
          "Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">
          "Clinical manifestations and diagnosis of psoriatic arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">
          "Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">
          "Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6058746">
         <span class="h1">
          TERMINOLOGY AND CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The terms "spondyloarthropathy" and "spondyloarthritis" are used to refer to a group of related seronegative (ie, rheumatoid factor-negative) inflammatory diseases generally characterized by involvement of the spine (sacroiliitis and spondylitis), large joints (most frequently lower limb asymmetric oligoarthritis), and entheses (enthesitis or enthesopathy; inflammation of the sites where tendons, ligaments, or joint capsule insert into the bone). Spondyloarthritides are strongly associated with the presence of human leukocyte antigen (HLA) B27. The term "spondyloarthritis" primarily includes children meeting criteria for the juvenile idiopathic arthritis (JIA) categories of enthesitis related arthritis (ERA) and psoriatic arthritis [
         <a href="#rid2">
          2
         </a>
         ] but also encompasses children with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Juvenile ankylosing spondylitis (JAS)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reactive arthritis (see
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory bowel disease (IBD)-associated arthritis (see
         <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">
          "Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         ERA and JAS identify similar groups of patients, with the criteria for JAS requiring radiologic evidence of bilateral sacroiliitis. The classification of JIA is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6412.html" rel="external">
          "Classification of juvenile idiopathic arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enthesitis related arthritis (ERA) accounts for approximately 10 to 19 percent of children classified with juvenile idiopathic arthritis (JIA) [
         <a href="#rid3">
          3-6
         </a>
         ]. The mean age at diagnosis for children with ERA is approximately 12 years [
         <a href="#rid6">
          6
         </a>
         ]. ERA is more common in males, who make up approximately 60 to 80 percent of cases [
         <a href="#rid6">
          6,7
         </a>
         ]. It is estimated that approximately 8 to 11 percent of adults with ankylosing spondylitis (AS) had onset of their disease in childhood [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">
          "Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7795.html" rel="external">
          "Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis"
         </a>
         .)
        </p>
        <p>
         The epidemiology of all forms of JIA and specifically psoriatic JIA, reactive arthritis, and inflammatory bowel disease (IBD) associated arthritis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6429.html" rel="external">
          "Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">
          "Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases", section on 'Prevalence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3929247">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The underlying etiology of spondyloarthritis is unknown. There is a strong association with human leukocyte antigen (HLA) B27, and an infectious etiology has been suggested but not proven. In addition, alterations in gut microbiota may be a contributing factor [
         <a href="#rid9">
          9
         </a>
         ]. Various animal models, including an HLA-B27 transgenic rat that may develop psoriasis, axial and peripheral arthritis, and colitis, are helping to shed light on this disorder [
         <a href="#rid10">
          10
         </a>
         ]. The pathogenesis of spondyloarthritis, particularly ankylosing spondylitis (AS) in adults, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7792.html" rel="external">
          "Pathogenesis of spondyloarthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1699359722">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is frequently a familial pattern to the spondyloarthropathies and related disorders. Patients with positive human leukocyte antigen (HLA) B27 and no family history of ankylosing spondylitis (AS) have a 1 to 3 percent lifetime risk of AS, whereas AS is 10 to 20 times more common in relatives of patients with AS, and the frequency is even higher in siblings of patients with AS [
         <a href="#rid8">
          8,11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7792.html" rel="external">
          "Pathogenesis of spondyloarthritis", section on 'Genetic factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The disease onset is typically insidious, although it may become evident following a febrile illness or musculoskeletal trauma in some cases [
         <a href="#rid12">
          12
         </a>
         ]. Examples of presenting features include a swollen ankle, a sausage digit, or what appears to be recurrent tendonitis. Morning stiffness is common, especially in the affected joint or lower back, and is responsive to heat (such as a long morning shower) or nonsteroidal antiinflammatory drugs (NSAIDs).
        </p>
        <p>
         Children with spondyloarthropathies initially may be misdiagnosed with recurrent sprains or strains since the onset of symptoms is often early in the second decade and frequently coincides with a period of increased physical activity. In addition, children may lack axial and/or extraarticular manifestations on presentation, with some of the features associated with the spondyloarthropathies, including inflammatory bowel disease (IBD), psoriasis, and ankylosing spondylitis (AS), only becoming clinically evident after the original presentation with enthesitis related arthritis (ERA) [
         <a href="#rid13">
          13
         </a>
         ]. Over time, these children may develop definite sacroiliitis [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7792.html" rel="external">
          "Pathogenesis of spondyloarthritis"
         </a>
         and
         <a class="local">
          'Laboratory testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6412.html" rel="external">
          "Classification of juvenile idiopathic arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2407340936">
         <span class="h2">
          Articular manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         At disease onset, the arthritis is usually oligoarticular (involving ≤5 joints), asymmetric, and primarily involves the joints of the lower extremities. Enthesitis (inflammation of the sites where tendons, ligaments, or joint capsule insert into the bone) is present in approximately 66 to 82 percent of children with ERA or juvenile spondyloarthritis at disease onset [
         <a href="#rid7">
          7
         </a>
         ]. The enthesitis also most commonly occurs in the lower extremities, specifically at the inferior pole of the patella, the plantar fascia insertion at the calcaneus, and insertion of the Achilles tendon at the calcaneus.
        </p>
        <p>
         Approximately 10 to 24 percent of children have axial involvement (spondylitis, sacroiliitis) at disease onset, which most frequently presents as spinal or sacroiliac joint pain and stiffness [
         <a href="#rid7">
          7,8,15
         </a>
         ]. Inflammatory back pain typically is insidious in onset, mostly worse at night, improves with exercise, and does not improve with rest. Some patients with sacroiliitis are asymptomatic [
         <a href="#rid16">
          16,17
         </a>
         ]. Others may present with hip or alternating buttock pain rather than back pain. Tarsitis (inflammation of the joints of the midfoot) presents as pain with movement of the foot, such as with walking or running. It is seen in approximately one-third of children with spondyloarthritis at disease onset and is more common in children with spondyloarthritis than other categories of juvenile idiopathic arthritis (JIA) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Dactylitis is seen in some patients with reactive arthritis and psoriatic JIA. (See
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis", section on 'Musculoskeletal signs and symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Dactylitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7795.html" rel="external">
          "Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults", section on 'Musculoskeletal features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Extraarticular manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of extraarticular manifestations are associated with the spondyloarthropathies and may occur prior to or following the onset of musculoskeletal symptoms. The most common extraarticular manifestations are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anterior uveitis, particularly acute (symptomatic) anterior inflammation characterized by eye pain, photophobia, or conjunctival injection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diverse skin manifestations (eg, erythema nodosum, pyoderma gangrenosum, psoriasis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent gastrointestinal complaints (eg, abdominal pain, diarrhea)
        </p>
        <p>
        </p>
        <p>
         These extraarticular manifestations may occur as part of an undifferentiated spondyloarthritis. However, in other patients, the spondyloarthritis may be associated with another systemic disease, such IBD, psoriasis, or infection, in the case of reactive arthritis. Signs and symptoms suggestive of these disorders include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammatory bowel disease
         </strong>
         – Recurrent or persistent aphthous ulcers, uveitis, poor weight gain, decreased longitudinal growth, and persistent anemia. Studies in adults with undifferentiated spondyloarthritis or AS suggest that IBD may be the underlying cause in selected patients, and it has been shown that many children with spondyloarthritis also have subclinical gastrointestinal disease [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">
          "Growth failure and pubertal delay in children with inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">
          "Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psoriatic arthritis
         </strong>
         – Psoriatic rash and nail pits. (See
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reactive arthritis
         </strong>
         – Genitourinary symptoms; sometimes oral ulcers or psoriatic rash. (See
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2816058260">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H2125110187">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spondyloarthropathies may be difficult to identify early due to subtle signs and symptoms. Keys to proper recognition include a careful history and a complete physical examination, with a particular focus on the musculoskeletal examination, to detect one or more of the following exam findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oligoarthritis
         </strong>
         – Usually asymmetric and primarily involves the large joints of the lower extremities. Findings include swelling, tenderness, increased warmth, erythema, and limited range of motion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enthesitis
         </strong>
         – Most commonly at the patella and calcaneus. The primary finding is tenderness with palpation of the tendon and ligament insertion points. Other examples are Achilles pain and swelling if there is a retrocalcaneal bursitis or pain with walking due to a plantar fasciitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tarsitis
         </strong>
         – Pain or tenderness with movement of the midfoot that may be associated with arthritis of the first metatarsophalangeal joint.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Axial arthritis (spondylitis, sacroiliitis)
         </strong>
         – Inflammatory back pain may be accompanied by reduced anterior spinal flexion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The modified Schober test may be used to evaluate for lumbosacral spine involvement, particularly in patients who do not yet have radiographic evidence of sacroiliitis  (
         <a class="graphic graphic_picture graphicRef107609" href="/z/d/graphic/107609.html" rel="external">
          picture 1
         </a>
         ). To perform the Schober test, the patient stands erect, and the position of the fifth lumbar spinous process is marked by a pen. Another mark is made 10 cm above it in the midline, and a third mark is made 5 cm below. The patient then bends forward maximally without bending the knees. In normal individuals, the distance between the top and bottom points should increase by 6 cm or more.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The sacroiliac (SI) joints can be examined by direct palpation, compression of the pelvis, and/or Patrick’s maneuver  (
         <a class="graphic graphic_picture graphicRef99775" href="/z/d/graphic/99775.html" rel="external">
          picture 2
         </a>
         ), although these tests and the modified Schober have variable sensitivity and specificity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory work-up for a child with suspected spondyloarthritis is similar to that of children with juvenile idiopathic arthritis (JIA) in general and may include complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), human leukocyte antigen (HLA) B27, and antinuclear antibody (ANA). Additional labs may be indicated based upon other associated symptoms or clinical findings. Many children with a spondyloarthritis have normal laboratory findings even in the setting of active disease, although ESR and other laboratory markers of inflammation, including CRP and platelets, may be elevated in some cases. Anemia of chronic disease is sometimes present. More significant anemia and/or elevations in acute-phase reactants may be suggestive of associated inflammatory bowel disease (IBD). ANA positivity is more likely in psoriatic arthritis, particularly in patients who have a pattern more typical for an oligo- or polyarticular arthritis, but is uncommon other forms of spondyloarthritis. Rheumatoid factor is usually absent. (See
         <a class="medical medical_review" href="/z/d/html/6412.html" rel="external">
          "Classification of juvenile idiopathic arthritis"
         </a>
         .)
        </p>
        <p>
         HLA-B27 is present in 60 percent of children with spondyloarthritis and 90 percent of children with juvenile ankylosing spondylitis (JAS) [
         <a href="#rid10">
          10,12,21
         </a>
         ]. Although HLA-B27 occurs with an increased frequency in these children, the presence or absence of the allele cannot be relied upon to establish or refute the diagnosis. The rates of HLA-B27 vary by ethnicity. (See
         <a class="medical medical_review" href="/z/d/html/7792.html" rel="external">
          "Pathogenesis of spondyloarthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3722612635">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiographic findings are frequently normal at baseline. As the disease progresses, radiographic changes may be seen in the in the SI joints, vertebrae, pelvis, and entheseal insertion sites. Early in the disease course, SI changes are more frequently seen at the iliac side of the joint and the inferior, synovial aspect of the joint. Radiographic changes in the peripheral joints are similar in appearance to those associated with other categories of JIA.
        </p>
        <p>
         Magnetic resonance imaging (MRI) is significantly more sensitive in detecting early sacroiliitis than plain radiographs, and the earliest findings may include subchondral edema and periarticular bone marrow edema [
         <a href="#rid22">
          22-26
         </a>
         ]. MRI without gadolinium may be sufficient to identify sacroiliitis in children [
         <a href="#rid26">
          26
         </a>
         ]. Although the presence of bilateral inflammatory sacroiliitis on MRI strongly supports a diagnosis of a spondyloarthritis, approximately half of cases of inflammatory sacroiliitis are unilateral. Infectious and oncologic processes may also present in the SI joints, usually with unilateral involvement [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         Whole-body MRI has been preliminarily assessed as a means of diagnosing enthesitis related arthritis (ERA) and monitoring disease activity [
         <a href="#rid28">
          28
         </a>
         ]. However, additional data in children are required before this imaging study is incorporated into routine clinical care.
        </p>
        <p>
         Ultrasound (US) with power Doppler may have a role in the diagnosis and monitoring of enthesitis in these patients. However, additional data regarding the US appearance of normal pediatric entheses and the development of a standard scoring system for enthesitis are needed to support the incorporation of entheseal US into routine practice [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enthesitis related arthritis (ERA) is one of the categories of juvenile idiopathic arthritis (JIA) defined by the International League of Associations for Rheumatology (ILAR) [
         <a href="#rid30">
          30-32
         </a>
         ].
        </p>
        <p>
         ERA in children aged &lt;16 years is defined as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arthritis (persisting ≥6 weeks)
         <strong>
          and
         </strong>
         enthesitis (no specific duration required)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         OR
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arthritis or enthesitis, as above, with two of the following additional criteria present:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sacroiliac (SI) tenderness or inflammatory lumbosacral pain
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive human leukocyte antigen HLA-B27
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Onset of arthritis in a male &gt;6 years of age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute (symptomatic) anterior uveitis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         First-degree relative with ERA, sacroiliitis associated with inflammatory bowel disease (IBD), reactive arthritis, or acute anterior uveitis
        </p>
        <p>
        </p>
        <p>
         Juvenile ankylosing spondylitis (JAS) is defined similarly, with one additional requirement of radiologic evidence of bilateral SI inflammation [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
         The initial assessment also should include evaluation for systemic diseases that may manifest as spondyloarthritis. These diseases, which are discussed in detail separately, include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IBD (see
         <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">
          "Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases", section on 'Diagnosis'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psoriatic arthritis (see
         <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Diagnosis'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reactive arthritis (see
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis", section on 'Diagnosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         As noted above, the musculoskeletal manifestations of these disorders may precede other evidence of the underlying condition by months to years. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spondyloarthritis in general should be differentiated from musculoskeletal injuries or developmental abnormalities. Back pain and stiffness are rare in young children and uncommon in adolescents and usually require additional evaluation. Careful evaluation to eliminate orthopedic, neoplastic, and infectious etiologies is important. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2852.html" rel="external">
          "Back pain in children and adolescents: Causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2853.html" rel="external">
          "Back pain in children and adolescents: Evaluation"
         </a>
         .)
        </p>
        <p>
         Mechanical, developmental, and orthopedic disorders other than spondyloarthritis may cause hip pain in children. These include slipped capital femoral epiphysis, Legg-Calve-Perthes disease, and osteoid osteomas. Clinicians can typically distinguish these conditions from spondyloarthritis based upon the age of the patient and a complete history and physical examination. (See
         <a class="medical medical_review" href="/z/d/html/6554.html" rel="external">
          "Evaluation and management of slipped capital femoral epiphysis (SCFE)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">
          "Nonmalignant bone lesions in children and adolescents", section on 'Osteoid osteoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2856.html" rel="external">
          "Approach to hip pain in childhood", section on 'Common causes of hip pain in children'
         </a>
         .)
        </p>
        <p>
         Enthesitis may occur in isolation as a result of mechanical issues and overuse. Sever disease (calcaneal apophysitis), Osgood-Schlatter disease (apophysitis of the tibia tubercle), and Sindig-Larsen and Johansson syndrome (tendonitis involving the lower pole of the patella) may have similar physical exam findings to enthesitis at these sites and should also be considered in patients who have findings isolated to these sites. (See
         <a class="medical medical_review" href="/z/d/html/6460.html" rel="external">
          "Overview of the causes of limp in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6458.html" rel="external">
          "Evaluation of limp in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2856.html" rel="external">
          "Approach to hip pain in childhood"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6521.html" rel="external">
          "Forefoot and midfoot pain in the active child or skeletally immature adolescent: Overview of causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6522.html" rel="external">
          "Heel pain in the active child or skeletally immature adolescent: Overview of causes", section on 'Calcaneal apophysitis (Sever disease)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6289.html" rel="external">
          "Osgood-Schlatter disease (tibial tuberosity avulsion)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6515.html" rel="external">
          "Approach to chronic knee pain or injury in children or skeletally immature adolescents", section on 'Sinding-Larsen-Johansson disease (patellar apophysitis)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          COURSE AND PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enthesitis related arthritis (ERA) is a heterogeneous condition, and its course is difficult to predict. However, children with ERA have greater pain, stiffness, and reduced function [
         <a href="#rid33">
          33,34
         </a>
         ]; more refractory disease; are less likely to achieve inactive disease within the first year after initiation of treatment [
         <a href="#rid35">
          35
         </a>
         ]; and have lower rates of remission overall than other categories of juvenile idiopathic arthritis (JIA) [
         <a href="#rid36">
          36
         </a>
         ]. Patients can develop joint damage. It is not yet known how earlier diagnosis and the early use of tumor necrosis factor (TNF) alpha inhibitors may effect these outcomes.
        </p>
        <p>
         A number of variables are associated with poorer outcomes. The presence of human leukocyte antigen (HLA) B27 is associated with refractory disease, older age at disease onset, sacroiliitis, tenosynovitis, an increased number of active joints within the first three years after disease onset, involvement of small joints of the lower extremities in boys, and overall unfavorable outcome [
         <a href="#rid37">
          37
         </a>
         ]. Additional predictors of refractory disease include older age at disease onset, hip arthritis, and tarsitis [
         <a href="#rid10">
          10,16,36
         </a>
         ]. Other predictors of an unfavorable outcome include family history of related diseases, patient sex (female sex and poor long-term physical health status, male sex and reduced anterior flexion of the spine), a persistently elevated erythrocyte sedimentation rate (ESR), early hip or ankle arthritis, and high numbers of affected joints [
         <a href="#rid33">
          33,38
         </a>
         ]. Specific risk factors for development of sacroiliitis, in addition to the presence of HLA-B27, include higher numbers of active joints and sites of enthesitis at disease onset, hip arthritis, and elevated ESR [
         <a href="#rid33">
          33,39,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals for the treatment of spondyloarthritis in children are similar to that of other categories of juvenile idiopathic arthritis (JIA) and include preventing joint damage, controlling symptoms, and preserving functional ability. The approach to treatment for enthesitis related arthritis (ERA) and juvenile ankylosing spondylitis (JAS) is discussed here. The approaches for other forms of spondyloarthritis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/111392.html" rel="external">
          "Treatment of arthritis associated with inflammatory bowel disease", section on 'Treatment approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">
          "Reactive arthritis", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16366.html" rel="external">
          "Psoriatic juvenile idiopathic arthritis: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H633833717">
         <span class="h2">
          Pain relief
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonsteroidal antiinflammatory drugs (NSAIDs) are used to treat pain, stiffness, and enthesitis in children with spondyloarthropathies [
         <a href="#rid8">
          8,41
         </a>
         ]. Several NSAIDs have been approved for use in children with JIA, including
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          naproxen
         </a>
         ,
         <a class="drug drug_general" data-topicid="10295" href="/z/d/drug information/10295.html" rel="external">
          meloxicam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         , and
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         . Typical regimens are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          Ibuprofen
         </a>
         30 to 40 mg/kg/
         <strong>
          day
         </strong>
         in three to four divided oral doses (maximum dose 2400 mg/
         <strong>
          day
         </strong>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          Naproxen
         </a>
         15 to 20 mg/kg/
         <strong>
          day
         </strong>
         orally in two divided doses (maximum 500 mg twice daily)
        </p>
        <p>
        </p>
        <p>
         Many other NSAIDs are routinely used by pediatric rheumatologists but have not been specifically approved for use in children. These include
         <a class="drug drug_general" data-topicid="9781" href="/z/d/drug information/9781.html" rel="external">
          piroxicam
         </a>
         and
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         .
        </p>
        <p>
         NSAIDs are continued until symptoms improve, and then they are tapered as tolerated.
        </p>
        <p>
         Concerns regarding potential adverse effects exist for all NSAIDs and are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">
          "Overview of COX-2 selective NSAIDs", section on 'Toxicities and possible toxicities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3222071531">
         <span class="h2">
          Peripheral arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with peripheral joint disease who have failed NSAIDs or who are nonambulatory on presentation, intraarticular injection of glucocorticoids is the most frequently used therapy. They are a particularly good option when disease is oligoarticular (≤5 joints affected) [
         <a href="#rid8">
          8,41
         </a>
         ].
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          Triamcinolone
         </a>
         hexacetonide is the preferred formulation, but is not currently available due to lack of supply; an alternative is triamcinolone acetonide. Intraarticular glucocorticoids are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis", section on 'Initial therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6425.html" rel="external">
          "Joint aspiration or injection in children: Indications, technique, and complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7985.html" rel="external">
          "Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?"
         </a>
         .)
        </p>
        <p>
         For patients with more diffuse, polyarticular disease or oligoarticular disease refractory to NSAIDs and intraarticular glucocorticoids, options include oral glucocorticoids or disease-modifying antirheumatic drugs (DMARDs) [
         <a href="#rid8">
          8,41
         </a>
         ]. Given the well-established short- and long-term toxicities associated with oral glucocorticoids, they are not considered appropriate as long-term monotherapy for these patients. Of the DMARDs,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         has been shown to have some benefit for children with ERA who have primarily peripheral arthritis [
         <a href="#rid8">
          8,42
         </a>
         ].
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is commonly used as first-line therapy for children with other categories of JIA and has utility for peripheral arthritis in children with ERA. However, it has not been shown to be effective for children with axial disease [
         <a href="#rid43">
          43,44
         </a>
         ]. A biologic DMARD, specifically a tumor necrosis factor (TNF) inhibitor, is usually added if a patient failed to improve after intraarticular therapies or a trial of a conventional nonbiologic DMARD therapy. These therapies are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis", section on 'Escalation of therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6428.html" rel="external">
          "Polyarticular juvenile idiopathic arthritis: Treatment", section on 'Initial management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H764038491">
         <span class="h2">
          Axial arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with ERA and axial disease, first-line therapy is NSAIDs. For those who fail NSAIDs, TNF-alpha inhibitors, including
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         , are recommended for arthritis (both peripheral and axial) and enthesitis in children with ERA [
         <a href="#rid41">
          41,45-49
         </a>
         ] given the known poor response of axial disease to conventional DMARDs.
         <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">
          Secukinumab
         </a>
         (anti-interleukin [IL] 17A), was approved for active ERA in children ≥4 years of age based upon adult safety and efficacy data and pediatric safety data [
         <a href="#rid50">
          50
         </a>
         ]. It is an option for patients who are resistant to TNF inhibitors, particularly in those with psoriasis and arthritis. Additional biologics, including
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         (anti-IL-12/23), have shown promise in adult ankylosing spondylitis (AS) and are under evaluation in children. (See
         <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">
          "Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3443939191">
         <span class="h2">
          Physical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physical therapy to improve mobility and decrease stiffness is important in this type of arthritis, particularly if the back is involved.
        </p>
        <p class="headingAnchor" id="H3299011452">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118770.html" rel="external">
          "Society guideline links: Spondyloarthritis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112604.html" rel="external">
          "Society guideline links: Juvenile idiopathic arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11837775">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The terms "spondyloarthropathy" and "spondyloarthritis" are used to refer to a group of related seronegative (ie, rheumatoid factor-negative) inflammatory diseases characterized by involvement of the spine (sacroiliitis and spondylitis), large joints (asymmetric oligoarthritis, especially of the lower extremities), and entheses (enthesitis or enthesopathy, inflammation of the sites where tendons, ligaments, or joint capsule insert into the bone). Diseases that can fall under this category in children include undifferentiated spondyloarthritis, enthesitis related arthritis (ERA), ankylosing spondylitis (AS), psoriatic arthritis, reactive arthritis, and inflammatory bowel disease (IBD)-associated arthritis. (See
         <a class="local">
          'Terminology and classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ERA is a category of juvenile idiopathic arthritis (JIA) that includes children with arthritis and enthesis or arthritis and other features associated with spondyloarthritis. It excludes the reactive arthropathies, psoriatic JIA, and the arthropathy associated with IBD. (See
         <a class="local">
          'Terminology and classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The onset of the disease is often gradual but may be first recognized following a febrile illness or musculoskeletal trauma. The arthritis is usually oligoarticular, asymmetric, and primarily involves the large joints of the lower extremities. The knee, ankle, and mid-foot are the joints most frequently involved at presentation. Common associated features include painful tendon or ligament insertions (enthesitis), inflammatory back or sacroiliac (SI) joint pain, morning stiffness, and limited spinal mobility. (See
         <a class="local">
          'Articular manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extraarticular findings include anterior uveitis, diverse skin manifestations, and recurrent gastrointestinal complaints. These may be associated with undifferentiated spondyloarthritis or suggest an alternative diagnosis, including a related systemic disease (IBD, psoriatic arthritis, or reactive arthritis), or mechanical, developmental, and orthopedic disorders other than spondyloarthritis. (See
         <a class="local">
          'Extraarticular manifestations'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human leukocyte antigen (HLA) B27 is associated with ERA and is increased in frequency in all of the spondyloarthropathies. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="local">
          'Course and prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment of spondyloarthritis is aimed at reducing symptoms, controlling inflammation, and preventing disability. The appropriate treatment depends upon which manifestations are present, particularly whether there is axial disease and whether the spondyloarthritis is a manifestation of an associated systemic disease (ie, psoriatic JIA, reactive arthritis, IBD-associated arthritis). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1286234989">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Thomas JA Lehman, MD and Sarah Ringold, MD, MS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am 2002; 28:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demirkaya E, Ozen S, Bilginer Y, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol 2011; 29:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solau-Gervais E, Robin C, Gambert C, et al. Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France. Joint Bone Spine 2010; 77:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz M, Kendirli SG, Altintas DU, et al. Juvenile idiopathic arthritis profile in Turkish children. Pediatr Int 2008; 50:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saurenmann RK, Rose JB, Tyrrell P, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 2007; 56:1974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Klink AJ, Behrens EM, et al. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken) 2011; 63:1307.
          </a>
         </li>
         <li class="breakAll">
          Petty RE, Cassidy JT. Enthesitis-related arthritis (juvenile ankylosing spondylitis). In: Texbook of Pediatric Rheumatology, 6th ed., Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Elsevier Saunders, Philadelphia 2011. p.272.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll ML, Kumar R, Morrow CD, et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther 2014; 16:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol 2010; 37:2606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982; 100:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabral DA, Oen KG, Petty RE. SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992; 19:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989; 16:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos-Vargas R, Vázquez-Mellado J. The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 2010; 37:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Xiao R, Biko DM, Chauvin NA. Assessment of Sacroiliitis at Diagnosis of Juvenile Spondyloarthritis by Radiography, Magnetic Resonance Imaging, and Clinical Examination. Arthritis Care Res (Hoboken) 2016; 68:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Madrid C, Merino R, De Inocencio J, García-Consuegra J. Tarsitis as an initial manifestation of juvenile spondyloarthropathy. Clin Exp Rheumatol 2009; 27:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll ML, Patel AS, Punaro M, Dempsey-Robertson M. MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. Pediatr Rheumatol Online J 2012; 10:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll ML, Punaro M, Patel AS. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. J Rheumatol 2011; 38:2274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabral DA, Malleson PN, Petty RE. Spondyloarthropathies of childhood. Pediatr Clin North Am 1995; 42:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bollow M, Braun J, Biedermann T, et al. Use of contrast-enhanced MR imaging to detect sacroiliitis in children. Skeletal Radiol 1998; 27:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnini I, Savelli S, Matucci-Cerinic M, et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 2010; 37:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaremko JL, Liu L, Winn NJ, et al. Diagnostic utility of magnetic resonance imaging and radiography in juvenile spondyloarthritis: evaluation of the sacroiliac joints in controls and affected subjects. J Rheumatol 2014; 41:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herregods N, Jaremko JL, Baraliakos X, et al. Limited role of gadolinium to detect active sacroiliitis on MRI in juvenile spondyloarthritis. Skeletal Radiol 2015; 44:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Xiao R, Biko DM, et al. Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary? Arthritis Rheumatol 2015; 67:2250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber U, Maksymowych WP. Sensitivity and specificity of magnetic resonance imaging for axial spondyloarthritis. Am J Med Sci 2011; 341:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aquino MR, Tse SM, Gupta S, et al. Whole-body MRI of juvenile spondyloarthritis: protocols and pictorial review of characteristic patterns. Pediatr Radiol 2015; 45:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Chauvin NA, Klink AJ, et al. Detection of enthesitis in children with enthesitis-related arthritis: dolorimetry compared to ultrasonography. Arthritis Rheumatol 2014; 66:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colbert RA. Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond. Nat Rev Rheumatol 2010; 6:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flatø B, Hoffmann-Vold AM, Reiff A, et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 2006; 54:3573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss PF, Beukelman T, Schanberg LE, et al. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 2012; 39:2341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol 2011; 38:2675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flatø B, Aasland A, Vinje O, Førre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998; 25:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berntson L, Damgård M, Andersson-Gäre B, et al. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol 2008; 35:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berntson L, Nordal E, Aalto K, et al. HLA-B27 predicts a more chronic disease course in an 8-year followup cohort of patients with juvenile idiopathic arthritis. J Rheumatol 2013; 40:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnini I, Savelli S, Matucci-Cerinic M, et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 2010; 37:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 2010; 37:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol 2019; 71:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgos-Vargas R, Vázquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002; 61:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002; 41:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haibel H, Sieper J. Use of methotrexate in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28:S128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin Pharmacother 2007; 8:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009; 76:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otten MH, Prince FH, Twilt M, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol 2011; 38:2258.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504_S050_S051lbl.pdf.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6421 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12380369" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The juvenile-onset spondyloarthritides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14760812" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21269582" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20034832" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18353049" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Juvenile idiopathic arthritis profile in Turkish children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17530723" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21618453" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Enthesitis in an inception cohort of enthesitis-related arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21618453" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Enthesitis in an inception cohort of enthesitis-related arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25434931" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21123333" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The role of HLA-B27 in spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6608352" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6977633" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1404167" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2526221" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7779128" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20682668" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Spondyloarthritis in a pediatric population: risk factors for sacroiliitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26212574" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Assessment of Sacroiliitis at Diagnosis of Juvenile Spondyloarthritis by Radiography, Magnetic Resonance Imaging, and Clinical Examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19772808" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Tarsitis as an initial manifestation of juvenile spondyloarthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22316421" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21965700" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7567186" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Spondyloarthropathies of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9867178" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Use of contrast-enhanced MR imaging to detect sacroiliitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20810515" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Early predictors of juvenile sacroiliitis in enthesitis-related arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24634199" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Diagnostic utility of magnetic resonance imaging and radiography in juvenile spondyloarthritis: evaluation of the sacroiliac joints in controls and affected subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26201675" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Limited role of gadolinium to detect active sacroiliitis on MRI in juvenile spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25892309" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Detection of inflammatory sacroiliitis in children with magnetic resonance imaging: is gadolinium contrast enhancement necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358308" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sensitivity and specificity of magnetic resonance imaging for axial spondyloarthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25896337" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Whole-body MRI of juvenile spondyloarthritis: protocols and pictorial review of characteristic patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24449586" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Detection of enthesitis in children with enthesitis-related arthritis: dolorimetry compared to ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7473484" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Proposal for the development of classification criteria for idiopathic arthritides of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9779856" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20606622" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17075863" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23070991" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089470" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Attainment of inactive disease status following initiation of TNF-αinhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9489836" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18785306" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23547219" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : HLA-B27 predicts a more chronic disease course in an 8-year followup cohort of patients with juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20810515" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Early predictors of juvenile sacroiliitis in enthesitis-related arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20682668" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Spondyloarthritis in a pediatric population: risk factors for sacroiliitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31021537" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12228171" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12422010" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Is methotrexate effective in ankylosing spondylitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21044446" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Use of methotrexate in patients with ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15468375" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15986366" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17425478" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Adalimumab for the treatment of ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19070529" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21844151" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
